Last updated on August 2018

Biological Therapy in Treating Patients at High-Risk or With Lymphoma Lymphoproliferative Disease or Malignancies


Brief description of study

The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.

Clinical Study Identifier: NCT00002663

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.